What's Happening?
Siensmetrica, a company developing the AI-powered research analysis platform Tessa, has appointed Brian Napack, former CEO of Wiley, to its Advisory Board. Napack brings extensive experience in scientific publishing, education, and technology-enabled
information services. His career includes serving as President of Macmillan, Chairman of the Association of American Publishers, and a senior advisor at Providence Equity. Notably, he has also served on numerous corporate and nonprofit boards, including Houghton Mifflin Harcourt, Blackboard, and Ingram Industries. Siensmetrica's Tessa platform analyzes scientific literature using nearly 200 data points to generate trustworthiness metrics (TScores) and analytical frameworks, aiming to help researchers, clinicians, policymakers, and biopharma professionals evaluate the quality of published evidence.
Why It's Important?
The addition of Brian Napack to Siensmetrica's Advisory Board is significant for the U.S. scientific publishing and research evaluation landscape. His deep background, including his tenure at Houghton Mifflin Harcourt and Wiley, provides Siensmetrica with invaluable insight into the systems through which research is published, distributed, and evaluated. This expertise is crucial as Siensmetrica expands Tessa, its AI platform, to address the challenge of assessing the rigor and relevance of the ever-increasing volume of scientific literature. Napack's experience will help guide the integration of AI-based evidence assessment within established scientific publishing and research workflows, potentially influencing how research-intensive industries, such as biopharma, make critical decisions based on published evidence. This move could accelerate innovation and problem-solving by providing a more efficient and reliable method for evaluating scientific research.
What's Next?
With Brian Napack's appointment, Siensmetrica will continue to develop and scale its Tessa platform, leveraging his expertise to enhance the technology for users who rely on it for biomedical research evaluation. Napack's role will involve providing strategic input and guidance as Siensmetrica works to establish a consistent framework for evaluating the integrity and usefulness of scientific evidence. The company aims to make Tessa a scalable tool for biomedical decision-making, targeting research-intensive users including medical professionals, scientists, and biopharma organizations. This collaboration is expected to further refine Tessa's capabilities, ensuring that its AI-driven assessments are both robust and explainable, thereby fostering greater confidence in the scientific evidence used for critical decisions.
Beyond the Headlines
Napack's involvement highlights a growing trend where seasoned leaders from traditional publishing, including those with experience from educational giants like Houghton Mifflin Harcourt, are transitioning into the burgeoning field of AI-driven research evaluation. This convergence of traditional publishing knowledge with advanced technology signifies a critical shift in how scientific information is managed and consumed. The ethical and practical implications of AI in evaluating research are profound, particularly in ensuring transparency, explainability, and significance (T.E.S.)—Siensmetrica's proprietary framework. The challenge lies not just in automating literature review but in building trust in AI-generated assessments, especially when these assessments influence clinical and product-development strategies. This development could reshape the standards for scientific rigor and evidence-based decision-making across various U.S. industries.
